Biotechnology & Life Sciences Global On demand · 24-48h

Global Cell Gene Therapy Biomanufacturing Market Strategic Research Report

Global Cell Gene Therapy Biomanufacturing Market Strategic R…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Cell Gene Therapy Biomanufacturing Market
$16.52B2025
11%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Consumables, Equipment, Software Solutions

By Application: Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations, Cell Banks

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiva, Novasep

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 100 pages
Market size 2025
$16.52B
Billion USD
Forecast CAGR
11%
2025-2032
Forecast 2032
$34.3B
Projected
区域
5
Asia Pacific · Latin America · MEA · Europe · North America

概述

Scope of the Report

The global Cell Gene Therapy Biomanufacturing market size is predicted to grow from US$ 16,520 million in 2025 to US$ 33,850 million in 2032; it is expected to grow at a CAGR of 11.0% from 2026 to 2032.

Cell and gene therapy (CGT) includes the injection of cells, genes, or gene-modified cells into a patient with the purpose of preventing or treating a disease. Cell therapy involves the injection of cells to replace or aid the repair of damaged cells, whereas gene therapy involves the injection of genes into cells to alter the genetic makeup of the recipient cells. Cell-based gene therapies, such as chimeric antigen receptor T (CAR-T) therapy, represent combinations of both approaches.

In recent years, the demand for cell and gene therapy (CGT) has surged as the number of United States Food and Drug Administration (U.S. FDA)-approved CGT products has increased annually. This increasing demand underscores the pressing need for manufacturers to improve and advance their production processes to keep pace with the rapidly evolving CGT field. The entire CGT manufacturing process must occur in a facility that complies with good manufacturing practice (GMP) regulations and has received full authorization to manufacture CGTs or advanced-therapy medicinal products, as they are referred to in Europe, for human use. Numerous clinical trials have been conducted to assess the safety and efficacy of CGTs for a wide range of clinical indications, including cancer.

This report presents a comprehensive overview of the global Cell Gene Therapy Biomanufacturing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Consumables
  • Equipment
  • Software Solutions

Segment by Application

  • Life Science Companies
  • Contract Research Organizations
  • Contract Manufacturing Organizations
  • Cell Banks

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Cell Gene Therapy Biomanufacturing market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Cell Gene Therapy Biomanufacturing Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 11%
Regional growth momentum
Market share by segment
Key metrics
Base value
$16.52B
2025
Forecast
$34.3B
2032
CAGR
11%
2025–2032
区域
5
global
Key companies
Lonza GroupThermo Fisher Scientific Inc.Merck KGaAWuXi AppTecCatalent, Inc.Samsung BiologicsFUJIFILM Diosynth BiotechnologiesCharles River Laboratories
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
ConsumablesEquipmentSoftware Solutions
By Application
Life Science CompaniesContract Research OrganizationsContract Manufacturing OrganizationsCell Banks

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Consumables
  • 3.1.3 Equipment
  • 3.1.4 Software Solutions
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Life Science Companies
  • 4.1.3 Contract Research Organizations
  • 4.1.4 Contract Manufacturing Organizations
  • 4.1.5 Cell Banks
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Lonza Group
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Thermo Fisher Scientific Inc.
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Merck KGaA
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 WuXi AppTec
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Catalent, Inc.
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Samsung Biologics
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 FUJIFILM Diosynth Biotechnologies
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Charles River Laboratories
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Cytiva
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Novasep
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Cell Gene Therapy Biomanufacturing market?
The global Cell Gene Therapy Biomanufacturing market is estimated at US$ 16.52 billion in 2025 (base year) and is projected to reach US$ 33.85 billion by 2032.
What is the forecast CAGR for the Cell Gene Therapy Biomanufacturing market?
The market is expected to grow at a CAGR of 11.0% from 2026 to 2032, expanding from US$ 16.52 billion in 2025 to US$ 33.85 billion in 2032, roughly 2.0 times its base-year value.
What is Cell Gene Therapy Biomanufacturing?
Cell and gene therapy (CGT) includes the injection of cells, genes, or gene-modified cells into a patient with the purpose of preventing or treating a disease. Cell therapy involves the injection of cells to replace or aid the repair of damaged cells, whereas gene therapy involves the injection of genes into cells to alter the genetic makeup of the recipient cells. Cell-based gene therapies, such as chimeric antigen receptor T (CAR-T) therapy, represent combinations of both approaches.
How is the Cell Gene Therapy Biomanufacturing market segmented by type?
By type, the market is segmented into Consumables, Equipment and Software Solutions.
What are the key applications of Cell Gene Therapy Biomanufacturing?
Key applications covered include Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations and Cell Banks.
Which companies are profiled in the Cell Gene Therapy Biomanufacturing market report?
Key players profiled include Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies and Charles River Laboratories, among 10 companies covered in total.
What geographies does the Cell Gene Therapy Biomanufacturing market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Cell Gene Therapy Biomanufacturing market report?
The report is intended for manufacturers and solution providers, distributors and end users in Life Science Companies, Contract Research Organizations and Contract Manufacturing Organizations, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Cell Gene Therapy Biomanufacturing market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.